Home / Press & media / Articles


Below you will find editorial articles published on PEPTONIC medical’s activities, the development of the drug Vagitocin® and benefits of the hormone oxytocin.  The material is presented in chronological order.

2017-05-24, Life Science Sweden, Mikael Mildén

Peptonic satsar receptfritt

När gelen mot vaginal atrofi visade sig fungera lika bra utan den aktiva substansen oxytocin, väljer Peptonic att lansera den receptfritt.

Läs artikeln på lifesciencesweden.se »
Ladda ner PDF »


Recent Comments

    All press releases on Spotlightstockmarket.com

    All published press releases from PEPTONIC medical is available on spotlightstockmarket.com.

    About us

    PEPTONIC Medical is an innovative Swedish pharmaceutical company developing and commercializing safe and effective products for the treatment of menopausal symptoms, such as vaginal atrophy. VagiVital® is a registered trademark of PEPTONIC Medical. The product is being commercialised for the non-prescription use for the treatment of vaginal atrophy.

    The Company was founded in 2009 and its first candidate drug product is Vagitocin® – an estrogen-free oxytocin based product for the treatment of vaginal atrophy in clinical development phase 2.

    Oxytocin has a long history of safe and effective medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women.